OneSpan Inc vs Personalis Inc. Common Stock — how do they compare? OneSpan Inc trades at $17.52 (market cap $648.23M), while Personalis Inc. Common Stock trades at $15.95 (market cap $1.70B). The key difference: Personalis Inc. Common Stock is far larger — about 2.6× OneSpan Inc's market cap, and OneSpan Inc pays a 2.96% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Personalis Inc. Common Stock for 0 Days on average.
| OSPN | PSNL | |
|---|---|---|
Market Cap | $648.23M | $1.70B |
Volume | 466,478 | 3,262,398 |
Sector | Technology | Health |
52-Week High | $18.42 | $18.38 |
52-Week Low | $10.15 | $5.04 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $617.31M | $1.52B |
Dividend Yield | 2.96% | — |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $18.20, up 1.96% with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 27.76% net margins and consistent earnings beats, though revenue growth remains modest. Analyst sentiment is positive with 67% buy ratings, while recent news highlights investor interest and product innovation with the DigipassONE launch.
The stock presents value appeal with a P/E under 10 and robust cash generation, but faces execution risks amid competitive pressures and declining net cash flow. Upside potential hinges on subscription revenue growth offsetting hardware declines, with investor focus on Q3 earnings delivery against expectations of $0.236 EPS.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →